- Home
- SWVL vs NXL Comparison
SWVL vs NXL Comparison
Compare SWVL & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWVL | NXL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 18.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SWVL | NXL |
|---|---|---|
| Price | $2.20 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 8.3K | ★ 118.5K |
| Earning Date | 09-08-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,329,423.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.10 | $0.70 |
| 52 Week High | $7.20 | $4.09 |
Technical Indicators
Market Signals| Indicator | SWVL | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 31.04 |
| Support Level | $2.20 | $0.93 |
| Resistance Level | $2.38 | $1.01 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 0.00 | 7.45 |
Price Performance
Historical ComparisonAbout SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.